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Obesity develops from perturbations of cellular bioenergetics, when energy uptake
exceeds energy expenditure, and represents a major risk factor for the development
of type 2 diabetes, dyslipidemia, cardiovascular disease, cancer, and other conditions.
Brown adipose tissue (BAT) has long been known to dissipate energy as heat and
contribute to energy expenditure, but its presence and physiological role in adult human
physiology has been questioned for years. Recent demonstrations of metabolically active
brown fat depots in adult humans have revolutionized current therapeutic approaches
for obesity-related diseases. The balance between white adipose tissue (WAT) and
BAT affects the systemic energy balance and is widely believed to be the key
determinant in the development of obesity and related metabolic diseases. Members
of the transforming growth factor-beta (TGF-β) superfamily play an important role in
regulating overall energy homeostasis by modulation of brown adipocyte characteristics.
Inactivation of TGF-β/Smad3/myostatin (Mst) signaling promotes browning of white
adipocytes, increases mitochondrial biogenesis and protects mice from diet-induced
obesity, suggesting the need for development of a novel class of TGF-β/Mst antagonists
for the treatment of obesity and related metabolic diseases. We recently described
an important role of follistatin (Fst), a soluble glycoprotein that is known to bind and
antagonize Mst actions, during brown fat differentiation and the regulation of cellular
metabolism. Here we highlight various investigations performed using different in vitro
and in vivo models to support the contention that targeting TGF-β/Mst signaling enhances
brown adipocyte functions and regulates energy balance, reducing insulin resistance, and
curbing the development of obesity and diabetes.
Keywords: brown adipose tissue, beige fat, obesity, myostatin, follistatin
INTRODUCTION
Obesity is a major health problem spreading at an epidemic pace
throughout the world without any sign of abatement. According
to the World Health Organization report, more than 1 billion
adults (∼ 15% of world population) are overweight [body mass
index (BMI) > 25] (Tseng et al., 2010). Over 300 million adults
are essentially obese (BMI> 30), and these numbers are expected
to increase bymore than 50% by the year 2015 (Tseng et al., 2010).
Understanding the cellular process responsible for metabolic per-
turbations that contribute to the expansion of adipose tissues
accompanying obesity is critical for the development of thera-
peutic interventions. Any treatment for obesity must reduce total
energy uptake, increase energy expenditure, or have an effect on
both of these processes. Standard clinical approaches such as calo-
rie restriction and exercise programs have limited effectiveness.
Anti-obesity drugs targeted against the site of excess fat storage are
mainly viewed as weight-loss drugs that modify the central ner-
vous system (Grundy, 2006). The potential strategies to achieve
weight-loss are to reduce energy intake by stimulating anorex-
igenic signals or by blocking orexigenic signals and to increase
energy expenditure (Isidro and Cordido, 2009). Although such
drugs have been used as anti-obesity drugs, only modest weight
loss for relatively shorter periods of time has been achieved
(Grundy, 2006). Therapeutic strategies available to combat the
increased rate of obesity are inadequate because of the inherent
resistance of human body to weight loss (Whittle et al., 2011).
At the same time, several safety concerns and issues related to
associated toxicity have led to the withdrawal of some of these
drugs (Ioannides-Demos et al., 2006; Elangbam, 2009). Targeting
energy expenditure pathways by activating BAT is therefore con-
ceived as a promising alternative strategy that could provide
significant potential health benefits when used either alone or
in combination with other approaches (Boss and Farmer, 2012;
Townsend and Tseng, 2014). Accordingly, there is a growing inter-
est in identifying such classes of drugs which would increase
adaptive thermogenesis by increasing brown fat differentiation
from progenitor cells, activate brown fat, and skeletal muscle ther-
mogenesis, or increase general mitochondrial uncoupling (Wu
et al., 2012; Harms and Seale, 2013).
ADIPOSE TISSUE BROWNING AND ENERGY METABOLISM
Metabolically active depots of brown adipose tissue (BAT) have
recently been identified in adult humans (Nedergaard et al., 2007;
van Marken Lichtenbelt et al., 2009; Virtanen et al., 2009). BAT
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exists in distinct locations in small animals and is innervated by
the sympathetic nervous system (SNS) (Farmer, 2008). In sharp
contrast to white adipose tissue (WAT) which is known to store
energy in the form of triglycerides in periods of excess energy
intake, BAT metabolizes stored energy to generate heat for ther-
mogenic purposes (Ouellet et al., 2012; Virtanen, 2014). The
dynamic process of fat deposition and mobilization are therefore,
two key functions of adipose tissues. Genetic fat-mapping exper-
iments indicate that BAT in the interscapular region and skeletal
muscle but not white adipose cells arise from Myf5+ precursor
cells (Kajimura et al., 2010). On the other hand, “brown-like”
fat cells are derived from non-Myf5 (Myf5−) lineage and are
called beige cells or brite (brown-in-white) cells (Seale et al., 2008;
Kajimura et al., 2010). However, this concept has recently been
challenged. Studies based on lineage analysis suggest that subsets
of white adipocytes originates from both Myf5+ and Myf5− pre-
cursors and respond to β3-adrenoceptor stimulation and there-
fore, brite adipocytes may also have multiple origins (Sanchez-
Gurmaches et al., 2012; Lee and Cowan, 2013; Rosenwald et al.,
2013). These brite cells possess the morphological and biochem-
ical characteristics of classical brown adipocytes, including the
expression of UCP1 and multilocular lipid droplets (Ohno et al.,
2012; Kajimura and Saito, 2014). Transdifferentiation allows effi-
cient conversion of white adipocytes to brown adipocytes and vice
versa (Frontini and Cinti, 2010; Yadav et al., 2011). In general,
cold exposure conditions promote white-to-brown adipocyte
conversion through beta (3)-adrenoceptor-mediated transdiffer-
entiation (Bartelt et al., 2011). A recent report also demonstrated
a bi-directional interconversion of brite and white adipocytes
(Rosenwald et al., 2013). Brite adipocytes change their morphol-
ogy and gene expression profile to that of white adipocytes under
warm adaptation, or after high fat diet, a conversion that is not
observed in classical brown adipocytes (Rosenwald et al., 2013).
Prospective studies in humans found detectable BAT in up to 96%
of healthy young adults but less often in older or obese subjects
(Saito et al., 2009; van Marken Lichtenbelt et al., 2009; Ouellet
et al., 2011). Human brown adipocytes possess molecular sig-
natures that resemble brite cells (Sharp et al., 2012; Wu et al.,
2012). It is, therefore, logical to speculate that human adipocytes
might convert from brite into white adipocyte phenotype dur-
ing aging. There is a growing list of compounds that induce
browning of white adipocytes and therefore, have the ability to
modulate overall energy metabolism (Nedergaard and Cannon,
2014). Therapeutic potential of both kinds of adipose cells which
are regulated differently have been demonstrated. Genetic manip-
ulations to induce more brown or beige fat are associated with
significant anti-obesity and anti-diabetic actions in mice (Wu
et al., 2012; Harms and Seale, 2013). Upon cold exposure, heat
production in the animals is facilitated by the release of cate-
cholamines, which activate thermogenesis and the dissipation of
heat. This specialized function of BAT is derived from high mito-
chondrial content and the ability to express uncoupling protein-1
(UCP 1), a proton transporter that uncouples electron transport
from ATP production, allowing the energy to dissipate as heat
(Ohno et al., 2012; Wu et al., 2012). Transgenic mice expressing
UCP1 from the fatty acid binding protein 4 (FABP4) promoter
are resistant to genetic and diet-induced obesity (Kopecky et al.,
1995). Several transcriptional factors and cofactors affect the
expression of Ucp1, and other key brown fat-selective genes have
been identified. PRDM16, a 140kD zinc-finger protein is highly
enriched in BAT compared to WAT. This protein is also shown to
be selectively expressed in subcutaneous white adipocytes relative
to other white fat depots (Seale et al., 2011). Ectopic expression of
PRDM16 induces a nearly complete brown fat genetic program,
including mitochondrial biogenesis, increased cellular respira-
tion, and expression of brown-selective genes (Seale et al., 2008).
Differential gene expression analysis between beige and brown fat
cells demonstrates a related but distinctly clear expression profile
(Wu et al., 2012). Epithelial V-like antigen 1 (EVA1) was highly
enriched in brown fat cells, while developmental transcription
factor (Tbx1), immune and inflammatory response molecules
such as Tbx1, and CD137, Tmem26, and Slc27a1 have been iden-
tified as key beige-selective markers (Wu et al., 2012). Increased
inflammation promotes alternative activation of macrophages
and supports the development of functional beige cells (Ganeshan
and Chawla, 2014; Mauer et al., 2014; Qiu et al., 2014).
TGF-β SUPERFAMILY, BROWN FAT, AND OBESITY
TGF-β/ SMAD3/ACTIVIN RECEPTOR IIB SIGNALING AND ENERGY
METABOLISM
The transforming growth factor-β (TGF-β) superfamily is com-
prised of over 30 members that include several structurally
dimeric cytokines such as TGF-β, activins, and bone mor-
phogenic proteins (BMPs)/growth and differentiation factors
(GDFs) which are evolutionarily highly conserved (Shi and
Massagué, 2003). TGF-β transmits its signals via dual ser-
ine/threonine kinase receptors and transcription factors called
Smads. Several direct and indirect links between TGF-β and
mitochondrial energy metabolism and energy sensing path-
ways have been reported (Casalena et al., 2012). TGF-β over-
expression deregulates the cellular redox state by stimulating
reactive oxygen species (ROS) production through Nox4 acti-
vation and compromises the antioxidant system that protect
against mitochondrial derived ROS by inhibiting the expression
of MnSOD (Michaeloudes et al., 2011). TGF-β also modulates
energy metabolism by controlling mitochondrial metabolism
directly by reduction of complex IV and mitochondrial respi-
ration that results in increased ROS production (Yoon et al.,
2005). Extensive interaction between TGF-β and key energy sen-
sors adenosinemonophosphate-activated protein kinase (AMPK)
and sirtuin family members has been demonstrated (Mishra
et al., 2008; Verdin et al., 2010). TGF-β levels correlate with
obesity in mice (Samad et al., 1999) and humans (Alessi et al.,
2000; Fain et al., 2005). Furthermore, TGF-β/Smad3 path-
way has also been demonstrated in the regulation of insulin
gene transcription and β-cell function (Lin et al., 2009). Most
recently, a comprehensive study highlighted the critical involve-
ment of TGF-β/Smad3 signaling during the process of obesity
and demonstrated the beneficial effects of systemic blockade
of this signaling from obesity, diabetes, and hepatic steatosis
(Yadav et al., 2011). Using hyperinsulinemic-euglycemic clamp
experiments, this group reported that Smad3 loss protects exper-
imental mice from diet-induced obesity and insulin resistance.
This effect was associated with the phenotypic transition of white
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to BATs, induction of mitochondrial biogenesis, and enhanced
expression of BAT-related gene signatures. Furthermore, elevated
plasma TGF-β1 levels were shown to correlate positively with
BMI and increased adiposity in overweight and obese subjects
compared to subjects with normal BMI. Inhibition of activin
receptor IIB (ActRIIB) that integrates actions of TGF-β related lig-
ands via dimerization with Alk4/5 and signals intracellularly via
Smad2/3 promotes differentiation of primary brown adipocytes
in vitro and increases the amount of brown but not white fat in
mice (Fournier et al., 2012). This blockade of ActRIIB enhanced
mitochondrial function and uncoupled respiration resulted in
increased energy expenditure under ambient or cold tempera-
tures but not at thermoneutrality. Interestingly, molecular sig-
natures induced by inhibition of ActRIIB overlap with PGC-1α
overexpression in vivo. PGC-1α was originally described as a co-
activator of PPAR-γ that modulated expression of key brown fat
specific UCP-1 and thermogenesis in brown fat (Boström et al.,
2012).
MYOSTATIN REGULATION OF BROWN FAT AND ENERGY METABOLISM
Myostatin (Mst), also termed as growth/differentiation factor-8
(GDF-8) is a member of the TGF-β superfamily that regulates
skeletal muscle mass (McPherron et al., 1997). Mst-deficient
mice are significantly larger than wild type animals and show
widespread increase in skeletal muscle mass. Initial phenotypic
characterization of Mst-deficient mice revealed suppression of
body fat accumulation, an unexpected finding that suggested a
possible role of Mst in the control of energy balance beyond
its effect on skeletal muscle (McPherron and Lee, 2002). Using
muscle (gastrocnemius and levator-ani) and adipose (epididy-
mal and subcutaneous) tissues isolated from wild type and
Mst-deficient male mice, Braga et al. demonstrated significant
induction of BAT-related markers in both tissue types obtained
from Mst-deficient mice. Protein expression levels of adipocyte
specific marker adiponectin and energy sensing AMP-activated
protein kinase (AMPK) was significantly upregulated in differ-
entiating MEFs from Mst-deficient cells compared to the wild
type (Braga et al., 2013). In order to clarify how Mst defi-
ciency affects the body fat mass and energy balance, Choi et al.
compared rates of oxygen consumption, body composition, and
food intake in wild type, heterozygous and Mst-deficient mice
and reported significantly increased energy expenditure in Mst-
deficient mice (Choi et al., 2011). These studies suggested that
increased fatty acid oxidation and total energy expenditure could
be key reasons for reduced adiposity in Mst-deficient mice.
Significantly increased muscle mass in Mst deficient mice also
contributes to overall metabolism through inhibition of activin
signaling, activation of AMPK/PGC-1α/Fndc5 (irisin) pathway,
or by increasing Akt signaling (Guo et al., 2009; Shan et al., 2013).
Subsequent studies demonstrated remarkable changes in the epi-
didymal WAT of Mst-deficient mice compared to the wild type
mice. Global gene expression analysis of these mice revealed ele-
vated expression of genes involved in fatty acid oxidation, lipid
transport, mitochondrial biogenesis, and BAT-specific transcrip-
tion factors including Ucp1, Cidea, and Dio2 (Zhang et al., 2012).
Histological analysis of WAT explants derived from Mst-deficient
mice revealed the presence of BAT-like cells characterized by
their small diameter, inclusion of multilocular lipid droplets
and positive staining for UCP1. Also, these Mst-deficient mice
had higher body temperature (∼ 1◦C) compared to the wild
type mice. In the same study, the authors reported an increased
abundance and activity of energy sensing enzyme AMP-activated
protein kinase (AMPK) in adipose, liver, and skeletal muscle
tissues of Mst-deficient mice. Subsequently several lines of evi-
dence obtained from in vitro studies confirmed the inhibitory
role of Mst during brown fat differentiation and regulation
of energy metabolism. Brown preadipocyte cells obtained from
mouse interscapular BAT, when treated with recombinant Mst
protein significantly down-regulated brown adipocyte differen-
tiation via regulation of Smad3-mediated β-catenin stabilization
(Kim et al., 2012). Using primary cultures of mouse embryonic
fibroblasts (MEFs) obtained from wild type and Mst-deficient
embryos differentiating under specialized adipogenic conditions
that allows brown adipose-like differentiation, it was demon-
strated that the Mst-deficient group had significantly increased
levels of select genes and proteins that improve lipid metabolism
and energy expenditure (Braga et al., 2013). Treatment of dif-
ferentiating Mst-deficient MEFs with recombinant Mst protein
significantly inhibited the gene expression levels of key BATmark-
ers (Ucp1, and Prdm16), general adipocyte markers (Cebp-α, and
Pparγ) also expressed in BAT, metabolic regulators (Pgc-1α/β)
as well as BAT inducer (Bmp7). Activation of AMPK-PGC-1α
pathway in WATs of Mst-deficient mice was further confirmed
by other investigators (Shan et al., 2013). Immunohistochemical
staining of WAT from Mst-deficient mice showed numerous
small-sized brown adipocyte-like cells filled with multilocular
lipid droplets that stained with UCP1, typical characteristics of
beige cells. Consistent with the browning phenotype, WAT from
Mst-deficient mice also expressed significantly higher levels of
beige cell specific Tmem26 and Cd137. These authors further
demonstrated that loss of Mst or inhibition of Mst signaling
in preadipocytes was unable to account for the browning phe-
notype observed in WAT of Mst-deficient mice and suggested
that muscle-derived newly discovered myokine irisin (Fndc5)
was responsible for the browning in a non-autonomous manner
(Shan et al., 2013). Irisin was initially discovered as a PGC-
1α-dependent myokine that is responsible for brown-fat-like
characteristics both in vitro and in vivo and protects mice from
diet-induced obesity (Boström et al., 2012). The authors further
demonstrated that the effect of Mst inhibition on Pgc-1α and
Fndc5 gene expression are abolished by compound C (AMPK
inhibitor) suggesting that AMPK activation is required to mediate
the effect of Mst on Pgc-1α and Fndc5. Activation of AMPK sig-
naling pathway in Mst-deficient mice has also been reported pre-
viously that resulted in increased fatty acid oxidation, augmented
SIRT1 signaling, and increased sensitivity to insulin (Zhang et al.,
2011). The precise mechanism by which Mst inhibition may lead
to the upregulation of AMPK is not clear. It is possible that Mst
inhibition may regulate mTOR and FoxO1 pathways involved in
muscle protein synthesis and degradation, respectively to increase
the protein level of AMPK (McFarlane et al., 2006; Rodriguez
et al., 2011). Most recently, Mst has been reported to inhibit
AMPK in cardiomyocytes through the activation of TAK1, which
is the main signal transducer of Mst besides Smads (Biesemann
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et al., 2014). In conclusion, these studies provide rational justifi-
cation for inhibiting Mst through a novel class of Mst antagonists
for treatment of obesity and related metabolic syndromes by
enhancing brown adipocyte characteristics and increased energy
expenditure not only in white adipocytes but also in skeletal
muscle. A brief summary of TGF-β/Mst action on browning of
white adipocytes and regulation of energy metabolism is shown
in Figure 1.
FOLLISTATIN REGULATION OF BROWN FAT AND ENERGY METABOLISM
Follistatin (Fst) is a secreted glycoprotein that has been recog-
nized for many years as a high affinity binding and neutralizing
protein for several members of the TGF-β superfamily including
activins and Mst (Welt et al., 2002; Sidis et al., 2006). A series of
genetic studies have convincingly demonstrated an essential role
of Fst in skeletal muscle development (Matzuk et al., 1995; Lee
et al., 2010). However, the role of Fst in other metabolic tissues
is less well-known. Fst-deficient mice created by a targeted dele-
tion of the Fst gene survived until birth but died within hours of
delivery (Matzuk et al., 1995). Several defects, including reduced
size of intercostal and diaphragm muscle, were observed in these
mice, and these severe musculoskeletal defects were suggested as
FIGURE 1 | Inhibition of TGF-β/Mst/Smad3 signaling induces browning
of white adipocytes and regulates overall energy metabolism. Act RIIB:
Activin receptor type IIB; Pgc-1α: peroxisomal proliferator-activated receptor
(PPAR) coactivator 1; Bmp7: bone morphogenic protein 7; Prdm16: PR
domain containing 16; Ucp1: uncoupling protein 1; AMPK: adenosine
monophosphate-activated protein kinase; WAT: white adipose tissue.
the possible cause of neonatal death for these mice. Since skele-
tal muscle and brown fat share Myf5+ as common precursor,
and there is an absolute requirement of brown fat to maintain
body temperature during first few hours of neonatal life, Braga
et al. tested possible novel role of Fst in regulating overall ther-
mogenic program (Braga et al., 2014). Initial gene expression
analysis of a mouse tissue panel prepared from C57BL6J mice
showed very high levels of Fst expression in BAT and skeletal
muscle; intermediate expression in inguinal WAT and liver, and
significant but lower levels in other metabolic tissues. Expression
levels of Fst along with other known brown adipocyte markers
were significantly induced from nearly undetectable levels after
differentiation of mouse brown preadipocyte cells. Furthermore,
treatment of the differentiating cells with the recombinant Fst
protein further upregulated the expression of several thermo-
genic genes including Ucp1 and Prdm16, suggesting a possible
role of Fst in the brown fat differentiation program. As direct
in vivo analysis of lipid and energy metabolism as well as brown
fat differentiation program in Fst-deficient mice was not possi-
ble because of perinatal death of Fst-deficient pups, Braga et al.
isolatedMEFs fromwild type and Fst-deficient embryos after het-
erozygous breeding and allowed these cells to undergo specialized
adipogenic differentiation conditions to assess possible defects
in lipid and energy metabolism in Fst-deficient MEF cultures
compared to the wild type (Braga et al., 2013). Surprisingly, a sig-
nificant lack of stimulation of key markers for lipid and energy
metabolism and mitochondrial biogenesis including Adn, Pgc1a,
Bmp7, Cidea, Cyt C, Thrsp, Hp, Acsl1, Pparg, and Cd36 amongst
others in Fst-deficient MEFs was observed in comparison to the
wild type MEFs. Treatment of these differentiating Fst-deficient
MEF cultures with recombinant Fst rescued the expression lev-
els of these thermogenic genes and proteins. Interestingly, using
a similar MEF-based approach Braga et al. also demonstrated
reciprocal effects on Bmp7, Pgc1a, and Cidea gene expression in
Mst-deficiency cultures compared to the wild type (Braga et al.,
2013), suggesting possible cross-talk between Mst and Fst path-
ways during brown fat differentiation. Since PGC-1α is known
to drive brown-fat-like development of white fat and thermo-
genesis (Boström et al., 2012), its reciprocal regulation by Fst
and Mst is quite logical. BMP7, a key regulator of brown adi-
pogenesis and energy expenditure (Tseng et al., 2008) is known
to be induced by Fst (Amthor et al., 2002), but antagonized
by Mst (Rebbapragada et al., 2003). Fst-deficient MEFs showed
decreased oxygen consumption rate (OCR) compared to the wild
type; but recombinant Fst rescued this respiration impairment
indicating the crucial role of Fst during maintenance of cellular
respiration. These findings therefore, suggest that Fst is a novel
modulator of brown fat differentiation and energy metabolism,
and its loss-of-function results in severe metabolic defects that
may be essential for survival. Follistatin like-3 (FSTL3), another
major Mst binding protein is reported to regulate fat mass and
glucose homeostasis, it is not known whether it also regulates
BAT mass and activity (Brown et al., 2011). FSTL3 knockout
mice developed distinct phenotypes including increased pan-
creatic islet number and size, decreased visceral fat mass, and
increased insulin sensitivity, suggesting that the role of Fsts may
be more complicated (Mukherjee et al., 2007). The molecular
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FIGURE 2 | Follistatin promotes adipocyte differentiation and energy metabolism. Fst KO: follistatin knock out; MEF: mouse embryonic fibroblasts; UCP1:
uncoupling protein 1; PRDM16: PR domain containing 16; PGC-1α: peroxisomal proliferator-activated receptor (PPAR) coactivator 1; BAT: brown adipose tissue.
mechanisms responsible for Fst-induced brown adipocyte char-
acteristics have not been investigated; however, it is possible that
Fst may antagonize components of theMst/TGF-β signaling path-
ways during the process. It will be interesting to explore whether
Fst antagonizes Mst/Smad3 signaling during adipocyte differ-
entiation and browning of white adipocytes. Myf5-expressing
precursor cells are found in skeletal muscle as well as in BAT.
It is possible that Fst may induce classical BAT mass and its
activity by directly targeting Myf5-expressing cells. On the other
hand, Fst may also target pp38 MAPK/Cox-2 pathways in Myf5-
negative cells to promote browning in WAT. Most recently, irisin,
a PGC-1α and exercise inducible myokine has been reported
to stimulate browning of WAT through p38 MAP Kinase and
ERK signaling (Zhang et al., 2014). Similar to irisin, Fst levels
also increase after exercise (Hansen et al., 2011). Furthermore,
recombinant Fst or anti-Mst antibody treatment of mouse mus-
cle cells increases irisin encoded Fndc5 gene (Shan et al., 2013).
It is, therefore, possible that Fst may engage irisin/Mst dependent
signaling to promote browning. Detailed in vivo studies using Fst-
transgenic mice expressing Fst under the control of both white
and brown adipose-specific promoters on their metabolic param-
eters including whole body energy expenditure, glucose toler-
ance, and insulin sensitivity would provide valuable information
regarding potential adipocyte-specific effects of Fst. Delineating
the specific tissue targets of Fst responsible for its regulation
of overall energy homeostasis would provide a novel therapeu-
tic approach for the treatment of obesity and related metabolic
syndromes. Initial gene therapy preclinical studies performed on
non-human primates demonstrate that sustained Fst expression
caused no aberrations in the structures or functions of a vari-
ety of organs, suggesting that Fst use in clinical settings may
be safe (Kota et al., 2009). A brief summary of Fst action in
adipocyte differentiation and energy metabolism is shown in
Figure 2.
SUMMARY
Several in vitro and in vivo data accumulated from various lab-
oratories in recent years support the concept that inhibition of
TGF-β superfamily/Mst either through pharmacological modu-
lation or genetic inactivation increases brown adipose charac-
teristics, enhances energy expenditure, and provides metabolic
benefits. Therefore, inhibition of TGF-β/Mst through a novel class
of antagonists could provide rationale justification not only for
promoting muscle mass as expected, but also for the treatment of
obesity and related metabolic syndromes. Because Fst is known
to antagonize Mst and inhibit overall TGF-β signaling, investigat-
ing the potential effects of Fst on brown adipocyte characteristics
is important. Current findings by Braga et al. present support-
ing evidence that Fst enhances the acquisition of brown adipocyte
characteristics in vitro and has therapeutic potential for the treat-
ment of obesity and related metabolic syndromes either alone or
in combination with other drugs.
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